Related Experiment Video
Updated: Jul 18, 2025
Viral Nanoparticles for In vivo Tumor Imaging
Published on: November 16, 2012
TLR Agonists Delivered by Plant Virus and Bacteriophage Nanoparticles for Cancer Immunotherapy
Eunkyeong Jung1, Young Hun Chung2,3, Nicole F Steinmetz1,2,3,4,5,6
1Department of NanoEngineering, University of California, San Diego, 9500 Gilman Dr., La Jolla, California 92093, United States.
Abstract:
Toll-like receptors (TLRs) are promising targets in cancer immunotherapy due to their role in activating the immune system; therefore, various small-molecule TLR agonists have been tested in clinical applications. However, the clinical use of TLR agonists is hindered by their non-specific side effects and poor pharmacokinetics. To overcome these limitations, we used plant virus nanoparticles (VNPs) and bacteriophage virus-like particles (VLPs) as drug delivery systems. We conjugated TLR3 or TLR7 agonists to cowpea mosaic virus (CPMV) VNPs, cowpea chlorotic mottle virus (CCMV) VNPs, and bacteriophage Qβ VLPs. The conjugation of TLR7 agonist, 2-methoxyethoxy-8-oxo-9-(4-carboxybenzyl)adenine (1V209), resulted in the potent activation of immune cells and promoted the production of pro-inflammatory cytokine interleukin 6. We found that 1V209 conjugated to CPMV, CCMV, and Qβ reduced tumor growth in vivo and prolonged the survival of mice compared to those treated with free 1V209 or a simple admixture of 1V209 and viral particles. Nucleic acid-based TLR3 agonist, polyinosinic acid with polycytidylic acid (poly(I:C)), was also delivered by CPMV VNPs, resulting in enhanced mice survival. All our data suggest that coupling and co-delivery are required to enhance the anti-tumor efficacy of TLR agonists and simple mixing of the VLPs with the agonists does not confer a survival benefit. The delivery of 1V209 or poly(I:C) conjugated to VNPs/VLPs probably enhances their efficacy due to the multivalent presentation, prolongation of tumor residence time, and targeting of the innate immune cells mediated by the VNP/VLP carrier.
Insights
Virus nanoparticles effectively deliver Toll-like receptor (TLR) agonists for cancer immunotherapy, enhancing immune cell activation and reducing tumor growth. Conjugation, not simple mixing, is key for improved anti-tumor efficacy and survival benefits.
Area of Science:
- Immunology
- Nanotechnology
- Oncology
Background:
- Toll-like receptors (TLRs) are crucial for immune activation and promising cancer immunotherapy targets.
- Small-molecule TLR agonists face clinical limitations due to side effects and poor pharmacokinetics.
- Virus-based nanoparticles offer a novel drug delivery system to overcome these challenges.
Purpose of the Study:
- To investigate the use of virus nanoparticles (VNPs) and virus-like particles (VLPs) as drug delivery systems for TLR agonists.
- To enhance the anti-tumor efficacy and pharmacokinetic properties of TLR agonists.
- To evaluate the impact of conjugation versus simple mixing on therapeutic outcomes.
Main Methods:
- Conjugation of TLR3 or TLR7 agonists to cowpea mosaic virus (CPMV) VNPs, cowpea chlorotic mottle virus (CCMV) VNPs, and bacteriophage Qβ VLPs.
- In vitro assessment of immune cell activation and cytokine production (interleukin 6).
- In vivo evaluation of tumor growth reduction and survival rates in mice models.
Main Results:
- Conjugation of a TLR7 agonist (1V209) to CPMV, CCMV, and Qβ VLPs potently activated immune cells and increased interleukin 6 production.
- Viral particle-conjugated TLR7 agonist significantly reduced tumor growth and prolonged survival in mice compared to free agonist or admixture.
- Delivery of a TLR3 agonist (poly(I:C)) via CPMV VNPs also enhanced mice survival.
Conclusions:
- Coupling TLR agonists to VNPs/VLPs is essential for enhancing anti-tumor efficacy.
- Simple mixing of agonists with viral particles does not provide survival benefits.
- VNPs/VLPs improve TLR agonist efficacy through multivalent presentation, prolonged tumor residence, and immune cell targeting.
Related Concept Videos
01:27Tumor Immunotherapy
01:29Microorganisms in Medicine and Therapeutics
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:50Transgenic Plants
The first-ever transgenic plant was a tobacco plant developed in 1983 that showed resistance against the tobacco mosaic virus. Since then, many transgenic plants have been developed and commercialized for improving the agricultural, ornamental, and horticultural value of a crop plant. Transgenic...
01:29Subviral Agents
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...